Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Expeditors International of Wshngtn Inc (EXPD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Expeditors International of Wshngtn IncTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Expeditors International of Wshngtn Inc vs Zimmer Biomet Holdings Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $180.96 (market cap $23.24B), while Zimmer Biomet Holdings Inc trades at $92.82 (market cap $17.44B). The key difference: Expeditors International of Wshngtn Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.07%). Which is the better fit depends on your goals.

EXPDZBH
Market Cap
$23.24B$17.44B
Sector
IndustrialsHealth
52-Week High
$178.22$107.71
52-Week Low
$111.37$79.58
Enterprise Value
$22.49B$24.49B
Dividend Yield
0.91%1.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Expeditors International of Wshngtn Inc

EXPD trades at $180.87, up 1.49% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, posting Q1 2026 EPS of $1.71 versus $1.33 expected. Revenue grew to $11.07B in 2025 with a 7.48% net margin and impressive 36.59% ROE. Recent dividend of $0.81 reinforces shareholder returns while cash flow trends show operational strength.

Despite trading above the $161.50 consensus target, EXPD's earnings momentum and operational efficiency support continued upside potential. Key risks include analyst skepticism with only 12% buy ratings and overbought technical conditions. The stock's premium valuation requires sustained execution amid transportation industry challenges and economic uncertainties.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $92.94, up 2.1% on the day, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 70% gross margin and positive cash flow trends, though net income margin has declined from 13.8% in 2023 to 8.6% in 2025. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase, indicating management confidence.

ZBH presents a moderate growth opportunity with a consensus price target of $97.67, offering ~5% upside. Risks include rising debt levels and competitive pressures in medical devices. Analyst sentiment is mixed with 40% buy ratings, but institutional activity and strategic acquisitions support a stable outlook for long-term investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Expeditors International of Wshngtn Inc

Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.

Read more on EXPD

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH